-
Benzinga's Top Pre-Market Losers
Monday, June 13, 2011 - 8:19am | 119Zion Oil & Gas Inc (NASDAQ: ZN) dipped 5.87% to $6.57 in the pre-market session. ZN's trailing-twelve-month ROE is -64.95%. Gilead Sciences Inc (NASDAQ: GILD) dropped 3.31% to $38.90 in the pre-market trading. GILD reported that it has received a subpoena from the US Justice Department...
-
Alnylam Appoints Akshay Vaishnaw as Chief Medical Officer
Monday, June 13, 2011 - 8:03am | 271Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has promoted Akshay K. Vaishnaw, M.D., Ph.D., to the new position of Chief Medical Officer. Dr. Vaishnaw previously held the title of Senior Vice President, Clinical Research. “We are...
-
Wedbush Maintains Outperform on Chelsea Therapeutics
Monday, June 13, 2011 - 7:50am | 106Wedbush is out with its report today on Chelsea Therapeutics (NASDAQ: CHTP), maintaining Outperform. In a note to clients, Wedbush writes, "We maintain our OUTPERFORM rating and fair value of $8. We believe the rise in CHTP resulted from the impact of data presented at ICPDMD and illustrate the...
-
Jefferies Reports a Positive Turn in European Opinions on Revlimid Maintenance
Monday, June 13, 2011 - 7:38am | 85According to a recent report from Jefferies, after speaking with 11 hematologists at the EHA meeting in London, Jefferies believes that the opinion of European physicians has turned positive on Revlimid maintenance and Celgene (NASDAQ: CELG). In the report, Jefferies said, "Of the 11 hematologists...
-
Piper Jaffray Reiterates Overweight on Regeneron Pharmaceuticals
Monday, June 13, 2011 - 7:33am | 67Piper Jaffray is out with its report today on Regeneron Pharmaceuticals (NASDAQ: REGN), reiterating Overweight. In a note to clients, Piper Jaffray writes, "We reiterate our Overweight rating and $62 target based on a proj. enterprise value of $5.26 billion. We add mid-12E cash of $311 million....
-
Jefferies Reports Incyte's Positive Feedback on Ruxolitinib at EHA
Monday, June 13, 2011 - 7:28am | 102According to a recent report from Jefferies, Incyte (NASDAQ: INCY) has received positive feedback from physicians on ruxolitinib at EHA. After speaking to six physicians regarding their feedback on ruxolitinib, Jefferies remains confident in ruxolitinib's approval and a successful product launch...
-
Piper Jaffray Maintains Overweight on Vertex Pharmaceuticals
Monday, June 13, 2011 - 7:23am | 144Piper Jaffray is out with its report today on Vertex Pharmaceuticals (NASDAQ: VRTX), maintaining Overweight. In a note to clients, Piper Jaffray writes, "Vertex reported positive 48-week STRIVE data for VX-770 in patients with Cystic Fibrosis with the G551D mutation. Previously reported lung...
-
Stocks To Watch For June 13
Monday, June 13, 2011 - 4:26am | 253Some of the stocks that may grab investor focus today are: China Cord Blood Corporation (NYSE: CO) reported a 62.8% surge in its fourth-quarter net income attributable to shareholders. CO's net income came in at RMB26.3 million ($4.0 million), up from RMB16.1 million, in the year-ago period. Its...
-
Stocks for the week ahead
Friday, June 10, 2011 - 6:45pm | 1547( click to enlarge ) We finally got the breakout in Oncothyreon Inc. (NASDAQ:ONTY). Shares rallied past resistance near $6.82 and hit my trigger to open positions. Watch the $7 as potential resistance. Let's keep an eye on ONTY as i think momentum will pick up again. ( click to enlarge...
-
Gilead Sciences Receives Subpoena from U.S. Department of Justice
Friday, June 10, 2011 - 4:15pm | 70Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has received a subpoena from the United States Attorney's Office for the Northern District of California requesting documents related to the manufacture, and related quality and distribution practices, of Atripla®, Emtriva®, Hepsera®,...
-
Rodman & Renshaw Reiterates Outperform Rating on Agenus
Friday, June 10, 2011 - 3:02pm | 128Rodman & Renshaw is out with a research report this afternoon, where it reiterates its Outperform rating on Agenus Inc. (NASDAQ: AGEN); it has a $2.00 price target on the stock. The R&R analysts cited the company's recent ASCO data, which updated survival results from an ongoing Phase 2...
-
Rodman & Renshaw Reiterates Agenus Market Perform, $2 PT
Friday, June 10, 2011 - 1:23pm | 98Rodman & Renshaw reiterated its Agenus (NASDAQ: AGEN) Market Perform rating and $2 price target in a research report published today. In the report, Rodman & Renshaw states, " We are reiterating our Market Outperform / Speculative Risk rating on Agenus with a 12-month target price of $2,...
-
8 Stocks With Significant Insider Buying
Friday, June 10, 2011 - 12:07pm | 556Insider Monkey provides free insider trading and hedge fund holdings data. We believe insiders have an edge over other investors because insiders know more about their companies than do outsiders. That's why insiders aren't allowed to trade based on material non-public information. Most insiders...
-
Options Brief: Celsion Corporation
Friday, June 10, 2011 - 11:49am | 103Shares of Celsion Corporation (NASDAQ: CLSN) are lower on the session by 5.90%, trading at $3.03. Overall call volume is now running at 4.55x the daily average, with 5% of all calls traded being purchases on the offer. 3,816 contracts have traded on the session so far. Celsion Corporation s an...
-
Vertex Pharmaceuticals Announces Phase 3 STRIVE Study of VX-770 Showed Durable Improvements in Lung Function and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis
Friday, June 10, 2011 - 11:01am | 167Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis. STRIVE was designed to evaluate VX-770 among 161 people 12...